Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(05)62739-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting murine metastatic cancers with cholera toxin A1-adjuvanted peptide vaccines.
Hum Vaccin Immunother
December 2025
TIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
The dissemination of tumor cells with ensuing metastasis is responsible for most cancer-related deaths. Cancer vaccines may, by inducing tumor-specific effector T cells, offer a strategy to eliminate metastasizing tumor cells. However, several obstacles remain in the development of effective cancer vaccines, including the identification of adjuvants that enhance the evolvement and efficacy of tumor-specific T cells.
View Article and Find Full Text PDFUnmasking the Neglected Cholera Outbreaks in Sub-Saharan Africa.
Int J Public Health
January 2025
Department of Molecular Biology and Biotechnology, Pan African University Institute of Basic Sciences, Technology and Innovation, Nairobi, Kenya.
The 30-year evolution of oral cholera vaccines: A case study of a collaborative network alternative innovation model.
PLOS Glob Public Health
January 2025
Global Health Centre, Geneva Graduate Institute, Genève, Switzerland.
Cholera outbreaks have been rapidly increasing around the world. While long-term cholera prevention and control measures rely on improvements in water, sanitation, and hygiene, oral cholera vaccines (OCVs) are used for prevention and control in the short-to-medium term. OCVs lack the market incentives available in other more profitable disease areas.
View Article and Find Full Text PDFGeographic disparities impacting oral vaccine performance: Observations and future directions.
Clin Exp Immunol
January 2025
Bill & Melinda Gates Foundation, Seattle, WA, USA.
Oral vaccines have several advantages compared with parenteral administration: they can be relatively cheap to produce in high quantities, easier to administer, and induce intestinal mucosal immunity that can protect against infection. These characteristics have led to successful use of oral vaccines against rotavirus, polio, and cholera. Unfortunately, oral vaccines for all three diseases have demonstrated lower performance in the highest-burden settings where they are most needed.
View Article and Find Full Text PDFProtection by natural cholera against later episodes of cholera over 10 years of follow-up in Matlab, Bangladesh: a retrospective cohort study.
Lancet Microbe
January 2025
International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; International Vaccine Institute, Seoul, South Korea; UCLA Fielding School of Public Health, Los Angeles, CA, USA; Vaccine Innovation Center, Korea University School of Medicine, Seoul, South Korea. Electronic address:
Background: Patients with cholera have been shown to be protected against subsequent cholera for 3 years after their initial episode. We aimed to assess protection at 10 years of follow-up.
Methods: In this retrospective cohort study, cohorts of patients treated for cholera (index patients) and contemporaneously selected age-matched individuals without cholera (controls), randomly selected from the population of Matlab, Bangladesh, were assembled between 1990 and 2009 and followed for up to 10 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!